



02-20-04

CASE 4-30827B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV36558857506

Express Mail Label Number

February 19, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

CLARKE ET AL.

APPLICATION NO: 10/718,209

FILED: NOVEMBER 20, 2003

FOR: COMBINATIONS OF FORMOTEROL AND FLUTICASONE  
PROPPIONATE FOR ASTHMA

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/930,337 filed August 15, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7809

Date: 2/18/04

  
D. Gabrielle Brouillette  
Agent for Applicants  
Reg. No. 51,384

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-30827B  
APPLICATION NO.  
10/718,209  
APPLICANT  
CLARKE ET AL.  
FILING DATE  
NOVEMBER 20, 2003Group  
1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,658,549	8/19/97	Akehurst et al.	424	45	5/19/95
	AB	6,030,604	2/29/00	Trofast	424	46	1/9/98
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	0 756 868	2/5/97	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2,088,877	6/16/82	GB			<input type="checkbox"/>	<input type="checkbox"/>
	AO	93/11743	6/24/93	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	93/15741	8/19/93	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	95/05805	3/2/95	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Barnes, "Efficacy of Inhaled Corticosteroids in Asthma," J Allergy Clin. Immunol., Vol. 102, No. 4, Part 1, pp. 531-537 (1998).
	AS	Dal Negro et al., "Chronic Airways Obstruction -- Responsiveness to Combined, Pressurized Salbutamol-Beclothemason Dipropionate (Ventolin Flogo*)", Clin. Trials J., "Vol. 20, No. 6, pp. 366-372 (1983).
	AT	Lipworth et al., "Effects of Treatment With Formoterol on Bronchoprotection Against Methacholine", Am. J. Med., Vol. 104, pp. 431-438 (1998).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

ATTY. DOCKET NO.

4-30827B

APPLICATION NO.

10/718,209

APPLICANT

CLARKE ET AL.

FILING DATE

NOVEMBER 20, 2003

Group

1614



(Use several sheets if necessary)

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	95/31964	11/30/95	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CB	96/19968	7/4/96	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CC	96/32151	10/17/96	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CD	97/47286	12/18/97	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CE	98/31352	7/23/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CF	98/34595	8/13/98	WO			<input type="checkbox"/>	<input type="checkbox"/>
	CG	98/41193	9/24/98				<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

*(Use several sheets if necessary)*



**ATTY. DOCKET NO.**  
4-30827B  
**APPLICATION NO.**  
10/718,209  
**APPLICANT**  
CLARKE ET AL.  
**FILING DATE**  
NOVEMBER 20, 2003

**Group**  
1614

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Merck Index, 12th Edition, p. 713.
DB	Merck Index, 12th Edition, p. 719.
DC	O'Connor, "Combination Therapy", Pulmonary Pharmacology & Therapeutics, Vol. 11, pp. 397-399 (1998).
DD	Pralong et al., "Les Bêta-2-Stimulants À Longue Durée D'Action Dans Le traitement De L'Asthme: Utiles Ou Dangereux?" Med. Hyg., Vol. 56, pp. 2322-2326 (1998).
DE	
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.